Silence Therapeutics plc (SLN)
NASDAQ: SLN · Real-Time Price · USD
6.88
+0.54 (8.52%)
At close: Dec 20, 2024, 4:00 PM
6.54
-0.34 (-4.94%)
After-hours: Dec 20, 2024, 5:54 PM EST
Silence Therapeutics Revenue
Silence Therapeutics had revenue of 1.14M GBP in the quarter ending September 30, 2024, a decrease of -59.19%. This brings the company's revenue in the last twelve months to 16.25M, down -42.07% year-over-year. In the year 2023, Silence Therapeutics had annual revenue of 25.38M with 44.99% growth.
Revenue (ttm)
16.25M GBP
Revenue Growth
-42.07%
P/S Ratio
13.96
Revenue / Employee
149,037 GBP
Employees
109
Market Cap
324.84M USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 25.38M | 7.87M | 44.99% |
Dec 31, 2022 | 17.50M | 5.09M | 40.97% |
Dec 31, 2021 | 12.42M | 6.94M | 126.59% |
Dec 31, 2020 | 5.48M | 5.24M | 2,145.49% |
Dec 31, 2019 | 244.00K | - | - |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Canopy Growth | 207.63M |
Cerus | 176.23M |
Rigel Pharmaceuticals | 157.37M |
Sage Therapeutics | 106.40M |
AVITA Medical | 60.04M |
Aclaris Therapeutics | 27.08M |
XOMA Royalty | 21.61M |
Nyxoah | 5.67M |
SLN News
- 3 days ago - Top 3 Health Care Stocks That May Explode In Q4 - Benzinga
- 12 days ago - Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting - Business Wire
- 25 days ago - Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference - Business Wire
- 4 weeks ago - Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst - Benzinga
- 4 weeks ago - Top 3 Health Care Stocks You'll Regret Missing In Q4 - Benzinga
- 4 weeks ago - Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting - Business Wire
- 5 weeks ago - Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Business Wire
- 5 weeks ago - Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference - Business Wire